A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer (OPAL)
Latest Information Update: 09 May 2025
At a glance
- Drugs Bevacizumab (Primary) ; Dostarlimab (Primary) ; Niraparib (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms OPAL
- Sponsors GlaxoSmithKline; GSK; TESARO
Most Recent Events
- 02 May 2025 Status changed from active, no longer recruiting to completed.
- 12 Aug 2024 Study phase changed from Phase 1/2 to Phase 2.
- 12 Aug 2024 Planned End Date changed from 31 Mar 2026 to 14 Apr 2027.